Carisoprodol is a centrally-acting prescription drug of known abuse. Upon ingestion it is rapidly metabolised to meprobamate, also a prescription drug with abuse potential. Current immunoassays are specific for carisoprodol and therefore have a short window of detection and, furthermore, are ineffective at detecting meprobamate. The current invention, underpinned by an antibody specific for meprobamate, overcomes these deficiencies.

Carisoprodol is a centrally-acting prescription drug of known abuse. Upon ingestion it is rapidly metabolised to meprobamate, also a prescription drug with abuse potential. Current immunoassays are specific for carisoprodol and therefore have a short window of detection and, furthermore, are ineffective at detecting meprobamate. The current invention, underpinned by an antibody specific for meprobamate, overcomes these deficiencies.

Reivindicacion 1 Un dispositivo de ruptura de liberacion controlada caracterizado porque comprende a) un nucleo que comprende al menos un agente activo y al menos un excipiente; b) una membrana semipermeable que encierra al nucleo y que comprende al menos un pasaje preformado que la atraviesa y una region debilitada; y c) una subcapa que controla la ruptura entre el nucleo y la membrana semipermeable donde la membrana semipermeable se rompe en una region debilitada durante el uso debido al incre...

A method of using carisoprodol phenytoin or fosphenytoin comprises informing a user that co-administration of carisoprodol with phenytoin or fosphenytoin results in an increase in free phenytoin blood levels a decrease in total phenytoin levels or both. In another embodiment a method of using carisoprodol phenytoin or fosphenytoin comprises informing a user that when co-administering carisoprodol with phenytoin or fosphenytoin the level of free phenytoin in a patient serum should be monitored th...

A method of using carisoprodol comprises informing a user that co-administration of carisoprodol with steady-state phenyloin results in an increase in free phenyloin blood levels a decrease in total phenyloin blood levels or both. In another embodiment a method of using carisoprodol comprises informing a user that when co-administering carisoprodol with steady-state phenyloin the level of free phenyloin in a patient serum should be monitored the level of total phenyloin should be monitored or bo...

? Una composición farmacéutica estable caracterizada porque contiene en forma combinada. un inhibidor de la COX II y un relajante muscular ambos de liberación inmediata. La composición farmacéutica de la reivindicación 1 caracterizada porque se encuentra en forma de tableta. La composición farmacéutica de una de las cláusulas 1 ó 2 caracterizada porque el inhibidor de la COX II es Meloxicam y el relajante muscular es Carisoprodol. La composición farmacéutica de una de las cláusulas 1 2 ó 3 carac...

The present invention provides a pharmaceutical composition or formulation in tablet form with proven stability and its production process. This formulation combines the therapeutic action of meloxicam as an anti-inflammatory and carisoprodol as an analgesic and anti-inflammatory which have advantageous effects when administered jointly that are not observed with the administration of the active components alone.

A method of using carisoprodol phenytoin or fosphenytoin comprises informing a user that co-administration of carisoprodol with phenytoin or fosphenytoin results in an increase in free phenytoin blood levels a decrease in total phenytoin levels or both. In another embodiment a method of using carisoprodol phenytoin or fosphenytoin comprises informing a user that when co-administering carisoprodol with phenytoin or fosphenytoin the level of free phenytoin in a patient serum should be monitored th...

Composicion farmacéutica o formulacion en forma de tabletas de estabilidad comprobada así como su proceso de obtencion esta formulacion combina la accion terapéutica de meloxicam como antiinflamatorio y carisoprodol como analgésico y antiinflamatorio que resulta efectos ventajosos al administrarse conjuntamente y que no se observan con la administracion de los componentes activos solos.